Nanoparticles: Advances in drug delivery systems

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Volumn 3, Issue 1, 2012, Pages 922-929

  Shinde, Nishikant C ^a   Keskar, Nisha J ^a   Argade, Prashant D ^a  

^a Affiliated to Savitribai Phule Pune University   (India)

Author keywords

Nanoparticles; Nanosuspension; Nanotechnology; Solid lipid nanoparticles (SLN)

Indexed keywords

CARBON NANOTUBE; DANAZOL; GOLD NANOPARTICLE; IBUPROFEN; INDOMETACIN; LIPOSOME; MAGNETIC NANOPARTICLE; NANOPARTICLE; NANOSHELL; NANOWIRE; SOLID LIPID NANOPARTICLE;

CONTROLLED DRUG RELEASE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; HYDROPHILICITY; HYDROPHOBICITY; LIPOSOMAL DELIVERY; NANOENCAPSULATION; NANOMEDICINE; NANOPORE; NANOTECHNOLOGY; PARTICLE SIZE; REVIEW;

EID: 84861958959     PISSN: None     EISSN: 09758585     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. http://www.cientifica.com/archives/000081.html
2. Melgardt M de Villiers. Pharm Tech 2008; 98.
3. Birrenbach G and Speicer R. J Pharm Sci 1976; 65: 1763.
4. Akerman ME, Chan WC, Laakkoen P, Bhatia SN. Proc Natl A Cade Sci USA 2002; 99:12617-21.
5. Marzola P et al. J drug target 2003; 1924.
6. Desai MP et al. Pharma RES 1996; 13: 1838-45.
7. Nishiyama N et. al. Adv Exp Med Biol 2003; 519: 155-77.
8. Quintana A, Piechler I, et.al. Pharma Res 2002; 19: 1310-16.
9. Ayutlede J, Gandhi M, et al. Biomacromolecules 2006; 7: 208-14.
10. Allel TM. Drugs 1997; 57: 8-14.
11. Thomas M, Kilbanov AM. Proc Natl Acad Sci USA 2003; 100: 9138-43.
12. Cherian AK, Rana AC, Jain SK. Drug Dev Indian Pharma 2000; 26: 459-63.
13. Smeets RM, Dekker NH, et al. Nano-Lett 2006; 6: 89-95.
14. Kataoka K, Harada, et al. Nano Lett 2001; 519: 155-177.
15. Chan WC, Maxwell DJ et al. Curr Opin Biotechnol 2002; 13: 40-46.
16. Donald T Haynie. Pharma Tech Drug Delivery 2008; S6-S10.
17. Babincova M, Babinnec P. Naturforsh 2001; 56: 909-11.
18. Muller RH, Bohm B etal. Nanosuspensions:A formulations approach for poorly soluble and poorly bioavailable drugs. In: DL Wise, Editor, Handbook of pharmaceutical released technology I st Edn, Marcel Dekker, New York, 2002: 345-357.
19. Duchene D, Ponchel G. Eur J Pharma Biopharma 1997; 44: 15-23.
20. Liversidge GC. Drug Nanocrystals for Improved Drug Delivery, In: Int Symp Control Release Bioact Matter, Workshop on particulate drug delivery system 1996, pp.23.
21. Pignatello R, Bucolo C, et al. Eur J Pharma Sci 2002; 16(1-2): 53-61.
22. Akerman ME, Chan WC, et al. Proc Natl Acd Sci. USA 2002; 99: 12617-21.
23. Hishiyama N, Kataoka K. Adv Exp Med Biol 2003; 519: 155-177.
24. Nagasaki Y, et al. Adv Drug Delivery Rev 2001; 47:113-15.
25. Vyas S.P and Malaiya A. Microencap 1989; 6: 493.
26. http://www.swissre.com,2004
27. Hameed Hyder MA. Nanotechnology and Environment: Potential applications and environmental implications of nanotechnology.www.nanoforum.de/datenien,2003
28. Allel TM. Drugs 1997; 57: 8-14.
29. Babincova M, Babinnec P. Naturforsh 2001; 56: 909-11.